NovoCure Statistics
Total Valuation
NovoCure has a market cap or net worth of $1.98 billion. The enterprise value is $1.70 billion.
| Market Cap | 1.98B |
| Enterprise Value | 1.70B |
Important Dates
The next confirmed earnings date is Thursday, July 25, 2024, before market open.
| Earnings Date | Jul 25, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NovoCure has 107.61 million shares outstanding. The number of shares has increased by 1.51% in one year.
| Shares Outstanding | 107.61M |
| Shares Change (YoY) | +1.51% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | 9.26% |
| Owned by Institutions (%) | 85.72% |
| Float | 97.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 909.09 |
| PS Ratio | 3.77 |
| Forward PS | 3.44 |
| PB Ratio | 5.51 |
| P/FCF Ratio | n/a |
| PEG Ratio | -0.47 |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.26, with a Debt / Equity ratio of 1.66.
| Current Ratio | 6.26 |
| Quick Ratio | 5.99 |
| Debt / Equity | 1.66 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 5.12 |
Financial Efficiency
Return on equity (ROE) is -50.30% and return on invested capital (ROIC) is -22.43%.
| Return on Equity (ROE) | -50.30% |
| Return on Assets (ROA) | -16.90% |
| Return on Capital (ROIC) | -22.43% |
| Revenue Per Employee | $361,775 |
| Profits Per Employee | -$132,651 |
| Employee Count | 1,453 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 3.57 |
Taxes
In the past 12 months, NovoCure has paid $20.44 million in taxes.
| Income Tax | 20.44M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.93% in the last 52 weeks. The beta is 0.69, so NovoCure's price volatility has been lower than the market average.
| Beta (5Y) | 0.69 |
| 52-Week Price Change | -52.93% |
| 50-Day Moving Average | 19.81 |
| 200-Day Moving Average | 15.40 |
| Relative Strength Index (RSI) | 49.66 |
| Average Volume (20 Days) | 1,925,529 |
Short Selling Information
The latest short interest is 6.19 million, so 5.75% of the outstanding shares have been sold short.
| Short Interest | 6.19M |
| Short Previous Month | 5.59M |
| Short % of Shares Out | 5.75% |
| Short % of Float | 6.32% |
| Short Ratio (days to cover) | 3.42 |
Income Statement
In the last 12 months, NovoCure had revenue of $525.66 million and -$192.74 million in losses. Loss per share was -$1.80.
| Revenue | 525.66M |
| Gross Profit | 393.30M |
| Operating Income | -214.14M |
| Pretax Income | -172.30M |
| Net Income | -192.74M |
| EBITDA | -203.08M |
| EBIT | -214.14M |
| Loss Per Share | -$1.80 |
Balance Sheet
The company has $873.75 million in cash and $595.26 million in debt, giving a net cash position of $278.49 million or $2.59 per share.
| Cash & Cash Equivalents | 873.75M |
| Total Debt | 595.26M |
| Net Cash | 278.49M |
| Net Cash Per Share | $2.59 |
| Equity (Book Value) | 359.36M |
| Book Value Per Share | 3.34 |
| Working Capital | 842.48M |
Cash Flow
In the last 12 months, operating cash flow was -$88.18 million and capital expenditures -$32.79 million, giving a free cash flow of -$120.97 million.
| Operating Cash Flow | -88.18M |
| Capital Expenditures | -32.79M |
| Free Cash Flow | -120.97M |
| FCF Per Share | -$1.13 |
Margins
Gross margin is 74.82%, with operating and profit margins of -40.74% and -36.67%.
| Gross Margin | 74.82% |
| Operating Margin | -40.74% |
| Pretax Margin | -32.78% |
| Profit Margin | -36.67% |
| EBITDA Margin | -38.63% |
| EBIT Margin | -40.74% |
| FCF Margin | -23.01% |
Dividends & Yields
NovoCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.51% |
| Shareholder Yield | -1.51% |
| Earnings Yield | -9.73% |
| FCF Yield | -6.11% |
Analyst Forecast
The average price target for NovoCure is $30.00, which is 63.04% higher than the current price. The consensus rating is "Buy".
| Price Target | $30.00 |
| Price Target Difference | 63.04% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 13.60% |
| EPS Growth Forecast (5Y) | -14.77% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NovoCure has an Altman Z-Score of 1.02 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.02 |
| Piotroski F-Score | 2 |